Sumeet Singh
Vice President, HEOR
Expertise:
Sumeet Singh is Vice President, HEOR at EVERSANA where he leads HEOR projects for Canadian and global pharmaceutical clients. Prior to joining EVERSANA, Sumeet held various leadership positions at Canada’s Drug Agency (formerly CADTH). He has 20 years of experience in health technology assessment and health economics. Sumeet completed a master’s degree in Health Research Methodology from McMaster University and a bachelor’s degree in Pharmacy from the University of Toronto.
Articles by Sumeet Singh
Navigating A New Era: Reflections on Canada’s Enhanced CDA-AMC Reimbursement Review Process
CDA-AMC’s recent enhancements to the reimbursement review process are reshaping the Canadian HTA landscape. With the first draft recommendations issued under the new framework in late 2025, clear themes are emerging that will influence how Sponsors prepare submissions in the year ahead. In this POV, Christine Malmberg, Sumeet Singh, and Kamalpreet Mann examine what these […]
Identifying Challenges and Solutions for Indirect Comparisons in Myasthenia Gravis
Generalized myasthenia gravis (gMG) is a rare condition characterized by muscle weakness due to reduced connectivity between nerves and muscles throughout the body. There are many newer treatments for gMG, but no clinical trials directly comparing them. Comparative effectiveness can instead be estimated using analyses known as indirect treatment comparisons (ITCs). There are many ITC […]
New Insights into Brain Volume Loss in MS
We are excited to announce that members of the EVERSANA team have contributed to a significant publication in BMC Neurology. The study, titled “Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies,” provides valuable insights into the effects of various treatments on brain volume loss (BVL) in patients with relapsing […]
Canadian Market Access Success Starts With the Right Partner
The Canadian market access and reimbursement environment is in an era of unprecedented change. HTA bodies are transforming their organizations to make review processes more efficient and give Canadians faster access to new drugs (e.g., Target Zero, time-limited recommendations, streamlined economic reviews, rolling reviews). At the same time, Canadian drug prices continue to be regulated […]
Navigating an Ever-evolving Canadian Market Access and Reimbursement Environment
These are just some of the trends currently shaping the Canadian market access environment. Achieving favourable market access and reimbursement outcomes for new treatments in this ever-changing landscape requires intimate knowledge of the Canadian landscape, processes and key stakeholders, careful strategic planning, sound tactics and skilled execution. Some key steps and considerations to maximize the […]